Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13—PE38QQR for recurrent malignant glioma
- 1 February 2005
- journal article
- clinical trial
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 102 (2) , 267-275
- https://doi.org/10.3171/jns.2005.102.2.0267
Abstract
Object. Convection-enhanced delivery (CED) is a novel method for delivering therapeutic agents to infiltrative brain tumor cells. For agents administered by CED, changes on magnetic resonance (MR) imaging directly resulting from catheter placement, infusion, and the therapeutic compound may confound any interpretation of tumor progression. As part of an ongoing multiinstitutional Phase I study, 14 patients with recurrent malignant glioma underwent CED of interleukin (IL) 13—PE38QQR, a recombinant cytotoxin consisting of human IL-13 conjugated with a truncated Pseudomonas exotoxin. Serial neuroradiographic changes were assessed in this cohort of patients. Methods. Patients were treated in two groups: Group 1 patients received IL13—PE38QQR before and after tumor resection; Group 2 patients received infusion only after tumor resection. Preoperative and postinfusion MR images were obtained prospectively at specified regular intervals. Changes were noted along catheter tracks on postresection MR images obtained in all patients. A simple grading system was developed to describe these changes. When MR imaging changes appeared to be related to IL13—PE38QQR, patients were followed up without instituting new antitumor therapy. Conclusions. As CED of therapeutic agents becomes more common, clinicians and investigators must become aware of associated neuroimaging changes that should be incorporated into toxicity assessment. We have developed a simple grading system to facilitate communication about these changes among investigators. Biological imaging modalities that could possibly distinguish these changes from recurrent tumor should be evaluated. In this study the authors demonstrate the challenges in determining efficacy when surrogate end points such as time to tumor progression as defined by new or progressive contrast enhancement on MR imaging are used with this treatment modality.Keywords
This publication has 20 references indexed in Scilit:
- Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a Phase I/II clinical studyJournal of Neurosurgery, 2004
- Convective distribution of macromolecules in the primate brain demonstrated using computerized tomography and magnetic resonance imagingJournal of Neurosurgery, 2003
- Molecular and Functional Imaging Technology for the Development of Efficient Treatment Strategies for GliomasTechnology in Cancer Research & Treatment, 2002
- Comparative follow-up of enhancement phenomena with MRI and Proton MR Spectroscopic Imaging after intralesional immunotherapy in glioblastomaCentral European Neurosurgery, 2002
- Local inflammation and devascularization — in vivo mechanisms of the “bystander effect” in VPC-mediated HSV-Tk/GCV gene therapy for human malignant gliomaCancer Gene Therapy, 2001
- Tissue Distribution and Antitumor Activity of Topotecan Delivered by Intracerebral Clysis in a Rat Glioma ModelNeurosurgery, 2000
- Limited Efficacy of the HSV-TK/GCV System for Gene Therapy of Malignant Gliomas and Perspectives for the Combined Transduction of the Interleukin-4 GeneHuman Gene Therapy, 1997
- Receptor for Interleukin (IL) 13 Does Not Interact with IL4 but Receptor for IL4 Interacts with IL13 on Human Glioma CellsJournal of Biological Chemistry, 1996
- Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusionJournal of Neurosurgery, 1995
- Convection-enhanced delivery of macromolecules in the brain.Proceedings of the National Academy of Sciences, 1994